According to a recent survey of the life medicine industry released by the Ernst & Young Dispute Coordination and Review Service (FIDS) in March 2015, more than 90% of global anti-corruption cases are related to third-party organizations, but only 65% The respondent company requires third-party organizations to abide by the company's anti-bribery rules. In the survey report, nearly 50% of the respondents believe that the anti-corruption policies implemented by the company are not ideal in terms of implementation. Since the British pharmaceutical giant GlaxoSmithKline was exposed to the bribery scandal, the global anti-corruption supervision of pharmaceutical companies has been increasing, and the monitoring methods and monitoring scope have shown new trends.
New compliance trends
According to Ernst & Young's survey report, as the global anti-corruption efforts continue to strengthen, any pharmaceutical company with close business relevance in the United States must comply with the Foreign Corrupt Practices Act. With the determination and enforcement of the Chinese government's anti-corruption, it also means that Chinese pharmaceutical companies with close business ties with the US will also face a stricter compliance system.
And the growing integration of pharmaceutical companies around the world can also be a source of corruption. According to Ernst & Young's survey report, in 2014, the total amount of mergers and acquisitions between biopharmaceutical companies exceeded 200 billion US dollars, which is twice the average annual transaction volume in the past decade. Therefore, this will require a more extensive and rigorous review and supervision system within the company so that the more important risk factors are.
Anti-corruption monitoring integrates into new scientific and technological forces
It is worth mentioning that according to Ernst & Young's survey report, the company's big data concept will be integrated into the future, in addition to the traditional methods of the internal audit department, the anti-corruption policy and training, and the in-depth verification of accounting accounts. Monitoring technology. Ernst & Young pointed out that Forensic Data Analytics is often equipped with highly specialized technical talents, with scientific technology and years of forensic experience to help regulators and commercial organizations make timely and informed decisions. By comparing each transaction, understanding trading behavior, and applying 6w factors (who, what, location, time, reason, method) to the transaction review, regulators will be better able to identify suspicious behavior, perceived internal controls, policies, and business. A vulnerability exists in the program. Through the monitoring and analysis of big data, it can help enterprises to monitor relevant information more actively, identify potential risks in a timely and effective manner, and reduce the financial losses that may be caused.
In addition to traditional monitoring areas including: dining and entertainment, academic reports, visits and education grants and sponsorships, future big data monitoring will focus more on monitoring social media, email, and smart phone push promotion information. Of course, monitoring of traditional areas such as publications and scientific medical liaison activities will not be relaxed.
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.kangnewpharmas.com